JP2024517942A5 - - Google Patents

Info

Publication number
JP2024517942A5
JP2024517942A5 JP2023569936A JP2023569936A JP2024517942A5 JP 2024517942 A5 JP2024517942 A5 JP 2024517942A5 JP 2023569936 A JP2023569936 A JP 2023569936A JP 2023569936 A JP2023569936 A JP 2023569936A JP 2024517942 A5 JP2024517942 A5 JP 2024517942A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517942A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/029305 external-priority patent/WO2022241287A2/en
Publication of JP2024517942A publication Critical patent/JP2024517942A/ja
Publication of JP2024517942A5 publication Critical patent/JP2024517942A5/ja
Pending legal-status Critical Current

Links

JP2023569936A 2021-05-13 2022-05-13 Gタンパク質共役受容体の調節剤 Pending JP2024517942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188342P 2021-05-13 2021-05-13
US63/188,342 2021-05-13
PCT/US2022/029305 WO2022241287A2 (en) 2021-05-13 2022-05-13 Modulators of g-protein coupled receptors

Publications (2)

Publication Number Publication Date
JP2024517942A JP2024517942A (ja) 2024-04-23
JP2024517942A5 true JP2024517942A5 (cg-RX-API-DMAC10.html) 2025-05-22

Family

ID=82019613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569936A Pending JP2024517942A (ja) 2021-05-13 2022-05-13 Gタンパク質共役受容体の調節剤

Country Status (20)

Country Link
US (2) US12281149B2 (cg-RX-API-DMAC10.html)
EP (1) EP4337682A2 (cg-RX-API-DMAC10.html)
JP (1) JP2024517942A (cg-RX-API-DMAC10.html)
KR (1) KR20240007251A (cg-RX-API-DMAC10.html)
CN (1) CN117980325A (cg-RX-API-DMAC10.html)
AU (1) AU2022272251A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023023559A2 (cg-RX-API-DMAC10.html)
CA (1) CA3220005A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003369A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023015805A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230530A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000247A (cg-RX-API-DMAC10.html)
EC (1) ECSP23093673A (cg-RX-API-DMAC10.html)
GE (1) GEAP202416419A (cg-RX-API-DMAC10.html)
IL (1) IL308392A (cg-RX-API-DMAC10.html)
JO (1) JOP20230291A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013492A (cg-RX-API-DMAC10.html)
PE (1) PE20240890A1 (cg-RX-API-DMAC10.html)
TW (1) TW202313666A (cg-RX-API-DMAC10.html)
WO (1) WO2022241287A2 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
KR20250140132A (ko) * 2023-01-18 2025-09-24 상하이 민웨이 바이오테크놀로지 씨오 엘티디 삼중 활성을 갖는 융합 단백질 및 그 용도
EP4716545A1 (en) * 2023-05-21 2026-04-01 Carmot Therapeutics Inc. Treatment of adults with overweight or obesity with or without weight-related comorbidities
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026030653A1 (en) 2024-07-31 2026-02-05 Carmot Therapeutics Inc. Synthesis of an intermediate and its use for the preparation of glp-1r/gipr agonists
WO2026027650A1 (en) 2024-08-02 2026-02-05 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-cyano-5-fluorophenyl)-2-methyl-propionic acid
TW202620036A (zh) 2024-09-27 2026-05-16 美商卡默療法股份有限公司 肽酪胺酸-酪胺酸(pyy)類似物及glp-1r促效劑之組合療法
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026099325A1 (en) * 2024-11-08 2026-05-15 F. Hoffmann-La Roche Ag X-β-ALA-GLU(OTBU)-GLY TETRAMER AND ITS USE IN SPPS SYNTHESIS
WO2026112366A1 (en) * 2024-11-20 2026-05-28 Carmot Therapeutics Inc. Treatment of steatotic liver disease associated with metabolic dysfunction
WO2026119942A1 (en) * 2024-12-05 2026-06-11 F. Hoffmann-La Roche Ag Synthesis of a peptide including stepwise sidechain preparation
WO2026119946A1 (en) * 2024-12-05 2026-06-11 F. Hoffmann-La Roche Ag Spps synthesis of a peptide with bsmoc-lys building block
WO2026119941A1 (en) * 2024-12-05 2026-06-11 F. Hoffmann-La Roche Ag Spps synthesis of a peptide comprising a fatty acid side chain
WO2026125207A1 (en) * 2024-12-09 2026-06-18 F. Hoffmann-La Roche Ag Process for the preparation of a x-beta-ala-glu(otbu)-gly tetramer by lpps and its use in spps synthesis
WO2026131797A2 (en) 2024-12-18 2026-06-25 F. Hoffmann-La Roche Ag Process for the preparation of a fatty acid compound
WO2026153900A1 (en) 2025-01-15 2026-07-23 F. Hoffmann-La Roche Ag Process for the preparation of a bsmoc-lys fatty acid compound
CN119930843B (zh) * 2025-01-22 2025-12-30 北京康乐卫士生物技术股份有限公司 具有glp和gip双重活性的融合蛋白及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
CN1364167A (zh) 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1235618A2 (en) 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
CA3134906A1 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
US20150087586A1 (en) 2012-03-29 2015-03-26 Cebix, Inc. Pegylated c-peptide
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
JP6548579B2 (ja) 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9766239B2 (en) 2013-03-13 2017-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Synbodies for detection of human norovirus
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015031268A1 (en) 2013-08-26 2015-03-05 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
EP3218414A1 (en) 2014-11-14 2017-09-20 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
GB2551945B (en) 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
TWI799680B (zh) 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
KR20220050820A (ko) 2020-10-16 2022-04-25 한미약품 주식회사 Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
CN114617956B (zh) 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
CN116635050A (zh) 2020-12-24 2023-08-22 韩美药品株式会社 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
IL310644A (en) 2021-08-23 2024-04-01 Lilly Co Eli Compounds and Methods for Liquid Phase Synthesis
EP4410827A4 (en) 2021-09-02 2026-04-29 Sunshine Lake Pharma Co Ltd GLP-1/GIP Dual Target Fusion Polypeptide and Protein and Their Applications
EP4436991A1 (en) 2021-11-22 2024-10-02 Sun Pharmaceutical Industries Limited Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof

Similar Documents

Publication Publication Date Title
JP2024156720A5 (cg-RX-API-DMAC10.html)
IL277495B1 (en) Modulators of g-protein coupled receptors
RU2121998C1 (ru) Производные пиримидина, способ их получения, фармкомпозиция
JP5946873B2 (ja) 合成トリテルペノイドおよび疾患の治療における使用方法
JP2021035955A (ja) 多発性硬化症を処置するためのs1p受容体モジュレーター
US8227456B2 (en) Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives
JP2000256194A (ja) 核内レセプタ作動薬およびその効果増強剤
US20100324134A1 (en) Medicament for preventive and/or therapeutic treatment of bowel disease
US20240166613A1 (en) Proxisome proliferator activated receptor (ppar) compounds and methods of using the same
JP2022500473A5 (cg-RX-API-DMAC10.html)
US20240067635A1 (en) Cromolyn derivatives and uses thereof
JP2022502501A5 (cg-RX-API-DMAC10.html)
JPWO2019131582A1 (ja) 含窒素6員環化合物
US20260053766A1 (en) (s)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (apl) for use in the treatment of non-alcoholic steatohepatitis (nash), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis
JP2025510512A5 (cg-RX-API-DMAC10.html)
TW202412761A (zh) 以ask1抑制劑治療器官疾病或病症的方法
JP2002356445A (ja) 多発性硬化症(ms)、他の脱髄症状ならびに末梢神経障害、特に有痛の神経障害および糖尿病性神経障害の多剤併用治療
JP6241974B1 (ja) 霊長類生体の脳内ampa受容体のイメージング方法、プログラム、及びスクリーニング方法
JP2023535224A5 (cg-RX-API-DMAC10.html)
EP1628630A2 (en) Method of mitigating the adverse effects of il-2
CA2661018C (en) Synthesis of propyl phenoxy ethers and use as delivery agents
JP2024026770A (ja) 医薬
WO2018131662A1 (ja) Ampa受容体に関連する疾患の予防及び/又は治療剤
JP2026509229A (ja) 多発性硬化症(MS)及び他の脱髄性、炎症性及び神経変性疾患の予防及び治療のためのエストロゲン受容体βリガンド
WO2007060976A1 (ja) 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物